

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF LAE002 (AFURESERTIB) PLUS FULVESTRANT IN PATIENTS WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER

This announcement is made by Laekna, Inc. (the “**Company**“, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to announce that first patient has been enrolled and the Group has commenced study recruitment in our Phase III clinical trial AFFIRM-205 in China for LAE002 (afuresertib, an oral AKT inhibitor) plus fulvestrant (the “**Combination Therapy**”) in patients with PIK3CA/AKT1/PTEN alterations and HR+/HER2- locally advanced or metastatic breast cancer (“**LA/mBC**”) (the “**Phase III Clinical Trial AFFIRM-205**”).

The Phase III Clinical Trial AFFIRM-205 is a multi-center, randomized, double-blind, placebo-controlled pivotal study to further assess the anti-tumor efficacy and safety of the combination therapy.

The results of our Phase Ib study in the Combination Therapy with 20 patients from U.S. and China has shown promising anti-cancer efficacy with a well-tolerated safety profile. The data of this study have been presented during a poster spotlight session at the 2023 San Antonio Breast Cancer Symposium (SABCS) in December 2023. We have enrolled 11 additional subjects in this Phase Ib study and further verified the promising anti-cancer efficacy with a well-tolerated safety profile indicated in the earlier stage of the study. The Group plans to present the clinical data of all enrolled patients and the patients with positive biomarker in this Phase Ib study in a scientific conference in second half of 2024.

The Group plans to bring this precision therapy to HR+/HER2- LA/mBC patients who are in need of novel treatment options.

RISK WARNING

LAE002 (AFURESERTIB) MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, May 30, 2024

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.